Bhakti Arondekar

Pfizer (United States) — United States

Economics, Econometrics and Finance · Social Sciences

20h-index1.7kcitations121works3.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Economic and Financial Impacts of Cancer(33), Prostate Cancer Treatment and Research(24), Health Systems, Economic Evaluations, Quality of Life(22), PARP inhibition in cancer therapy(22), BRCA gene mutations in cancer(20)

Publications120 total

Do trial benefits predict real-world gains in metastatic castration resistant prostate cancer
JNCI Cancer Spectrum·2025Open Access
Racial Differences in Survival and Healthcare Resource Utilization Among Medicaid-Insured Adults With Metastatic Prostate Cancer
Clinical Genitourinary Cancer·2024Open Access
Development of a Novel Patient-Reported Outcome Measure to Assess Symptoms and Impacts of Androgen Deprivation Therapy for Advanced Prostate Cancer
Advances in Therapy·2024· 1 citedOpen Access
Clinical characteristics, treatment patterns, and outcomes in adult patients with germline BRCA1/2-mutated, HER2-negative advanced breast cancer: a retrospective medical record review in the United States
Frontiers in Oncology·2024Open Access
Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations
Clinical Genitourinary Cancer·2024· 1 citedOpen Access
The Impact of Social Determinants of Health Beyond Race on Survival in Metastatic Prostate Cancer: A Systematic Literature Review
Journal of Clinical Pathways·2023
Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population
Prostate Cancer and Prostatic Diseases·2023· 91 citedOpen Access
The impact of race on survival in metastatic prostate cancer: a systematic literature review
Prostate Cancer and Prostatic Diseases·2023· 18 citedOpen Access
Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims
Advances in Therapy·2023· 8 citedOpen Access
CO71 The Impact of Socioeconomic Status (SES), Insurance Type, and Treatment Facility on Survival in Metastatic Prostate Cancer (MPC): A Systematic Literature Review (SLR) of Social Determinants of Health (SDOH)
Value in Health·2023Open Access
Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study
The Oncologist·2023· 34 citedOpen Access
Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study
The Oncologist·2023· 20 citedOpen Access
Abstract 930: Treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer harboring DDR mutations
Cancer Research·2023
Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
2023Open Access
Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
2023Open Access
Supplementary Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
2023Open Access
Supplementary Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
2023Open Access
Supplementary Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
2023Open Access
Supplementary Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
2023Open Access
Abstract P4-01-30: Real-world treatment patterns and survival among adults with metastatic breast cancer with BRCA1/2 mutations
Cancer Research·2023
page 1 of 6Next →

Frequent Co-authors

Alexander Niyazov(13), Girishanthy Krishnarajah(6), Reshma Mahtani(6), Katie Lewis(6), A. Rider(6), Michael P. Lux(6), Jasmina Ivanova(5), Terry A. Jacobson(4), Gregory A. Nichols(4), Lucy Massey(4), Stephen J. Freedland(3), Pedro C. Barata(3), Andrea Leith(3), Amanda Ribbands(3), Rachel Montgomery(3), Matthew Last(3), Lisa J. McGarry(3), Gregory J. E. Hill(3), Cristina Masseria(3), Michelle Skornicki(3)